Search
rilonacept (Arcalyst)
Indications:
- inflammation in cryopyrin-associated periodic syndromes
- refractory gout
- resolution & prevention of recurrent pericarditis [3]
Contraindications:
Pregnancy category: C [2]
Monitor:
- complete blood count (CBC) baseline & every 3 months [2]
Mechanism of action:
- dual IL-beta receptors chimerically attached to Ig Fc fragment
- interleukin-1 receptor antagonist
Notes:
- Manufacturer: Regeneron
- more expensive IL-1 inhibitor
Management:
- whenever possible bring patients up to date on vaccinations prior to initiating biologic immunosuppressive agent [2]
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
Related
interleukin-1 receptor antagonist protein; IL-1ra; IL-1RN; IRAP; IL1 inhibitor; ICIL-1RA (IL1RN, IL1F3, IL1RA)
General
biologic immunosuppressive agent (biologic agent, biologic immune modulator)
anti-inflammatory agent
receptor antagonist
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 16(2): 2009
New Drugs Approved by the FDA in 2008
Detail-Document#: 250213
(subscription needed) http://www.prescribersletter.com
- Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18, 19.
American College of Physicians, Philadelphia 2012, 2015, 2018, 2022
- Klein AL et al.
Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis.
N Engl J Med 2020 Nov 16; [e-pub].
PMID: 33200890
https://www.nejm.org/doi/10.1056/NEJMoa2027892